Digital Pathology

PreclinicalBiologic

FFondazione Policlinico Universitario Agostino Gemelli IRCCS

Digital Pathology is one of 51 biologic programs targeting Uveal Melanoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Uveal MelanomaActive, not recruiting

Uveal MelanomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

90 competitors in Uveal Melanoma

#DrugCompanyPhaseTrials

DTIC-Dome

Bayer

Phase 3

5 2

Koselugo

AstraZeneca

Phase 3

2 3

Yervoy

Bristol-Myers Squibb

Phase 2

12 4

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 3

1 5

Opdivo

Bristol-Myers Squibb

Phase 2

9 6

KIMMTRAK

IImmunocore Ltd

Phase 3

5 7

Keytruda

Merck & Co.

Phase 2

6 8

Sutent

Pfizer

Phase 2

2 9

Nexavar

Bayer

Phase 2

2 10

Mekinist

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Uveal Melanoma1 trial

Morphological, Genetic and Tumour Microenvironment Characterisation in Uveal Melanoma

Unknown status·FFondazione Policlinico Universitario Agostino Gemelli IRCCS··NCT05889481·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Digital Pathology. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Digital Pathology compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Digital Pathology. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fondazione Policlinico Universitario Agostino Gemelli IRCCS company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: FFondazione Policlinico Universitario Agostino Gemelli IRCCS

Digital Pathology

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Uveal Melanoma1 trial

References

Drug Info

Quick Facts

Related News